SML1710
Talniflumate
≥98% (HPLC)
동의어(들):
2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester
로그인조직 및 계약 가격 보기
크기 선택
5 MG
₩148,089
25 MG
₩600,373
₩148,089
출고 가능일2025년 4월 08일세부사항
모든 사진(1)
크기 선택
보기 변경
5 MG
₩148,089
25 MG
₩600,373
About This Item
실험식(Hill 표기법):
C21H13F3N2O4
CAS Number:
Molecular Weight:
414.33
UNSPSC 코드:
12352200
NACRES:
NA.77
₩148,089
출고 가능일2025년 4월 08일세부사항
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
색상
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
저장 온도
room temp
SMILES string
FC(F)(F)c1cc(ccc1)Nc2ncccc2C(=O)OC3OC(=O)c4c3cccc4
InChI
1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)
InChI key
ANMLJLFWUCQGKZ-UHFFFAOYSA-N
생화학적/생리학적 작용
Talniflumate is a phthalidyl ester of niflumic acid.[1] It acts as an anti-inflammatory molecule and a mucoregulator. Talniflumate is used as a potent therapeutic for cystic fibrosis, chronic obstructive pulmonary disease and asthma.[2] Talniflumate also inhibits the calcium-activated chloride channel hCLCA function, which is involved in mucus overproduction.[1]
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases GCNT3 expression and production of mucins in vivo and in vitro. Talniflumate improves responsiveness of pancreatic tumors to gefitinib. Talniflumate is a potent calcium-activated chloride channel (CaCC) blocker.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
Nancy M Walker et al.
The Journal of pharmacology and experimental therapeutics, 317(1), 275-283 (2005-12-16)
Intestinal disease in cystic fibrosis (CF) mice closely mirrors aspects of obstructive syndromes in CF patients. The pathogenesis involves accumulation of mucoid debris in the crypts that fuse with intestinal content to form obstructing mucofeculant impactions. Treatment involves modalities that
Talniflumate (Genaera).
Knight D.
Current Opinion in Investigational Drugs, 5(5), 557-562 (2004)
Hayley Pearson et al.
Thorax, 76(1), 64-72 (2020-10-29)
Human respiratory syncytial virus (HRSV) is a common cause of respiratory tract infections (RTIs) globally and is one of the most fatal infectious diseases for infants in developing countries. Of those infected, 25%-40% aged ≤1 year develop severe lower RTIs leading to
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
